정신의학에서의 약물유전학 현황

키워드

참고문헌 (36)

1. Ingelman-Sundberg M, "Polymorphic human cytochrome P450 enzymes : an opportunity for individualized drug treatment", Trends Pharmacol Sci, 20, pp.342~349 (1999)
2. Gonzalez FJ, "Pharmacogenetic phenotyping and genotyping", Clin Pharmacokinet, 26, pp.59~70 (1994)
3. Motulsky AG, "Drug reactions, enzymes, and biochemical genetics", J Am Med Assoc, 165, pp.835~837 (1957)
4. Kalow W, "Contribution of hereditary factors to the response to drugs", Fed Proc, 24, pp.1259~1265 (1965)
5. Mahgoub A, "Polymorphic hydroxylation of debrisoquine in man", Lancet, 2, pp.584~586 (1977)
6. David R Nelson, "Cytochrome P450 (CYP) gene superfamily", eLS (2021), Wiley[DOI]
7. Mulder H, "Prevalence of patients using drugs metabolized by cytochrome P4502D6 in different populations : a cross-sectional study", Ann Pharmacother, 41, pp.408~413 (2007)
8. Sakaeda T, "Pharmacogenetics of drug transporters and its impact on the pharmacotherapy", Curr Top Med Chem, 4, pp.1385~1398 (2004)
9. Stingl JC, "Genetic variability of drugmetabolizing enzymes : the dual impact on psychiatric therapy and regulation of brain function", Mol Psychiatry, 18, pp.273~287 (2013)
10. Nebert DW, "From human genetics and genomics to pharmacogenetics and pharmacogenomics : past lessons, future directions", Drug Metab Rev, 40, pp.187~224 (2008)
11. Ingelman-Sundberg M, "Influence of cytochrome P450 polymorphisms on drug therapies : pharmacogenetic, pharmacoepigenetic and clinical aspects", Pharmacol Ther, 116, pp.496~526 (2007)
12. Baumann P, "The AGNP-TDM expert group consensus guidelines : therapeutic drug monitoring in psychiatry", Pharmacopsychiatry, 37, pp.243~265 (2004)
13. Hall-Flavin DK, "Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting", Pharmacogenet Genomics, 23, pp.535~548 (2013)
14. Bousman CA, "Pharmacogenetic tests and depressive symptom remission : a metaanalysis of randomized controlled trials", Pharmacogenomics, 20, pp.37~47 (2019)
15. Jukić MM, "Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure : a retrospective study based on 2, 087 patients", Am J Psychiatry, 175, pp.463~470 (2018)
16. Solomon HV, "Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions", Psychiatry Res, 271, pp.604~613 (2019)
17. Jukic MM, "Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole : a retrospective, cohort study", Lancet Psychiatry, 6, pp.418~426 (2019)
18. Rosenblat JD, "Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies", J Clin Psychiatry, 78, pp.720~729 (2017)
19. Peterson K, "Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder", Psychopharmacology(Berl), 234, pp.1649~1661 (2017)
20. Maciel A, "Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings", Neuropsychiatr Dis Treat, 14, pp.225~230 (2018)
21. Hornberger J, "Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients", Am J Manag Care, 21, pp.e357~e365 (2015)[DOI]
22. Mitropoulos K, "Relevance of pharmacogenomics for developing countries in Europe", Drug Metabol Drug Interact, 26, pp.143~146 (2011)
23. Roederer MW, "Pharmacogenetics and rational drug use around the world", Pharmacogenomics, 12, pp.897~905 (2011)
24. Mrazek DA, "Psychiatric pharmacogenomic testing in clinical practice", Dialogues Clin Neurosci, 12, pp.69~76 (2010)
25. Pratt VM, "Recommendations for clinical CYP2C19 genotyping allele selection : a report of the association for molecular pathology", J Mol Diagn, 20, pp.269~276 (2018)
26. Nofziger C, "PharmVar GeneFocus : CYP2D6", Clin Pharmacol Ther, 107, pp.154~170 (2020)
27. Gaedigk A, "The CYP2D6 activity score : translating genotype information into a qualitative measure of phenotype", Clin Pharmacol Ther, 83, pp.234~242 (2008)
28. Lauschke VM, "Prediction of drug response and adverse drug reactions : from twin studies to next generation sequencing", Eur J Pharm Sci, 130, pp.65~77 (2019)
29. Fabbri C, "A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping", Transl Psychiatry, 10, pp.50~ (2020)
30. McGraw J, "Cytochrome P450 variations in different ethnic populations", Expert Opin Drug Metab Toxicol, 8, pp.371~382 (2012)
31. Lee SY, "Sequencebased CYP2D6 genotyping in the Korean population", Ther Drug Monit, 28, pp.382~387 (2006)
32. Lee SJ, "Discovery of novel functional variants and extensive evaluation of CYP2D6genetic polymorphisms in Koreans", Drug Metab Dispos, 37, pp.1464~1470 (2009)
33. Park IH, "Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment", Breast Cancer Res Treat, 131, pp.455~461 (2012)
34. 변지영, "CYP2D6 allele frequencies in Korean population, comparisonwith East Asian, Caucasian and African populations,and the comparison of metabolic activity of CYP2D6 genotypes", Archives of Pharmacal Research, 41(9), pp.921~930 (2018), 대한약학회
35. Kirchheiner J, "Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?", Nat Rev Drug Discov, 4, pp.639~647 (2005)
36. Swen JJ, "Pharmacogenetics : from bench to byte--an update of guidelines", Clin Pharmacol Ther, 89, pp.662~673 (2011)

관련 논문AI추천